Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study - PubMed (original) (raw)
Observational Study
. 2015 Jun;148(7):1340-52.e7.
doi: 10.1053/j.gastro.2015.03.006. Epub 2015 Mar 6.
Herbert L Bonkovsky 2, Robert Fontana 3, William Lee 4, Andrew Stolz 5, Jayant Talwalkar 6, K Rajendar Reddy 7, Paul B Watkins 8, Victor Navarro 9, Huiman Barnhart 10, Jiezhun Gu 10, Jose Serrano 11; United States Drug Induced Liver Injury Network
Collaborators, Affiliations
- PMID: 25754159
- PMCID: PMC4446235
- DOI: 10.1053/j.gastro.2015.03.006
Observational Study
Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study
Naga Chalasani et al. Gastroenterology. 2015 Jun.
Abstract
Background & aims: The Drug-Induced Liver Injury Network is conducting a prospective study of patients with DILI in the United States. We present characteristics and subgroup analyses from the first 1257 patients enrolled in the study.
Methods: In an observational longitudinal study, we began collecting data on eligible individuals with suspected DILI in 2004, following them for 6 months or longer. Subjects were evaluated systematically for other etiologies, causes, and severity of DILI.
Results: Among 1257 enrolled subjects with suspected DILI, the causality was assessed in 1091 patients, and 899 were considered to have definite, highly likely, or probable DILI. Ten percent of patients died or underwent liver transplantation, and 17% had chronic liver injury. In the 89 patients (10%) with pre-existing liver disease, DILI appeared to be more severe than in those without (difference not statistically significant; P = .09) and mortality was significantly higher (16% vs 5.2%; P < .001). Azithromycin was the implicated agent in a higher proportion of patients with pre-existing liver disease compared with those without liver disease (6.7% vs 1.5%; P = .006). Forty-one cases with latency ≤7 days were caused predominantly by antimicrobial agents (71%). Two most common causes for 60 DILI cases with latency >365 days were nitrofurantoin (25%) or minocycline (17%). There were no differences in outcomes of patients with short vs long latency of DILI. Compared with individuals younger than 65 years, individuals 65 years or older (n = 149) were more likely to have cholestatic injury, although mortality and rate of liver transplantation did not differ. Nine patients (1%) had concomitant severe skin reactions; implicated agents were lamotrigine, azithromycin, carbamazepine, moxifloxacin, cephalexin, diclofenac, and nitrofurantoin. Four of these patients died.
Conclusions: Mortality from DILI is significantly higher in individuals with pre-existing liver disease or concomitant severe skin reactions compared with patients without. Additional studies are needed to confirm the association between azithromycin and increased DILI in patients with chronic liver disease. Older age and short or long latencies are not associated with DILI mortality.
Keywords: DILI; DILIN; Idiosyncratic; Medication; Toxicity.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.
Comment in
- Drug-induced liver injury: expanding our knowledge by enlarging population analysis with prospective and scoring causality assessment.
Teschke R, Andrade RJ. Teschke R, et al. Gastroenterology. 2015 Jun;148(7):1271-3. doi: 10.1053/j.gastro.2015.04.027. Epub 2015 Apr 25. Gastroenterology. 2015. PMID: 25921378 No abstract available.
Similar articles
- Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study.
Molleston JP, Fontana RJ, Lopez MJ, Kleiner DE, Gu J, Chalasani N; Drug-Induced Liver Injury Network. Molleston JP, et al. J Pediatr Gastroenterol Nutr. 2011 Aug;53(2):182-9. doi: 10.1097/MPG.0b013e31821d6cfd. J Pediatr Gastroenterol Nutr. 2011. PMID: 21788760 Free PMC article. - Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study.
Chalasani N, Bonkovsky HL, Stine JG, Gu J, Barnhart H, Jacobsen E, Björnsson E, Fontana RJ, Kleiner DE, Hoofnagle JH; Drug-Induced Liver Injury Network (DILIN) Study Investigators. Chalasani N, et al. J Hepatol. 2022 Apr;76(4):832-840. doi: 10.1016/j.jhep.2021.12.013. Epub 2021 Dec 22. J Hepatol. 2022. PMID: 34953957 Free PMC article. - Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury.
Chalasani N, Li YJ, Dellinger A, Navarro V, Bonkovsky H, Fontana RJ, Gu J, Barnhart H, Phillips E, Lammert C, Schwantes-An TH, Nicoletti P, Kleiner DE, Hoofnagle JH; Drug Induced Liver Injury Network. Chalasani N, et al. J Hepatol. 2023 Feb;78(2):293-300. doi: 10.1016/j.jhep.2022.09.010. Epub 2022 Sep 22. J Hepatol. 2023. PMID: 36152763 Free PMC article. - Drug-induced liver injury.
Leise MD, Poterucha JJ, Talwalkar JA. Leise MD, et al. Mayo Clin Proc. 2014 Jan;89(1):95-106. doi: 10.1016/j.mayocp.2013.09.016. Mayo Clin Proc. 2014. PMID: 24388027 Review. - Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.
Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, Serrano J, Rochon J, Fontana RJ, Bonacini M; US Drug-Induced Liver Injury Network. Ghabril M, et al. Clin Gastroenterol Hepatol. 2013 May;11(5):558-564.e3. doi: 10.1016/j.cgh.2012.12.025. Epub 2013 Jan 17. Clin Gastroenterol Hepatol. 2013. PMID: 23333219 Free PMC article. Review.
Cited by
- Dietary Intake of Vegetables and Cooking Oil Was Associated With Drug-Induced Liver Injury During Tuberculosis Treatment: A Preliminary Cohort Study.
Wang J, Xiong K, Xu L, Zhang C, Zhao S, Liu Y, Ma A. Wang J, et al. Front Nutr. 2021 May 24;8:652311. doi: 10.3389/fnut.2021.652311. eCollection 2021. Front Nutr. 2021. PMID: 34109203 Free PMC article. - Dose- and time-dependent manners of moxifloxacin induced liver injury by targeted metabolomics study.
Hu T, Sun Y, An Z. Hu T, et al. Front Pharmacol. 2022 Sep 16;13:994821. doi: 10.3389/fphar.2022.994821. eCollection 2022. Front Pharmacol. 2022. PMID: 36188611 Free PMC article. - Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients.
Marie S, Frost KL, Hau RK, Martinez-Guerrero L, Izu JM, Myers CM, Wright SH, Cherrington NJ. Marie S, et al. Acta Pharm Sin B. 2023 Jan;13(1):1-28. doi: 10.1016/j.apsb.2022.08.018. Epub 2022 Aug 28. Acta Pharm Sin B. 2023. PMID: 36815037 Free PMC article. Review. - The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine.
Fontana RJ, Cirulli ET, Gu J, Kleiner D, Ostrov D, Phillips E, Schutte R, Barnhart H, Chalasani N, Watkins PB, Hoofnagle JH. Fontana RJ, et al. J Hepatol. 2018 Dec;69(6):1317-1325. doi: 10.1016/j.jhep.2018.08.004. Epub 2018 Aug 21. J Hepatol. 2018. PMID: 30138689 Free PMC article. - Rituximab-induced autoimmune hepatitis: A case study and literature review.
Galiatsatos P, Assouline S, Gologan A, Hilzenrat N. Galiatsatos P, et al. Can Liver J. 2020 Nov 17;3(4):381-386. doi: 10.3138/canlivj-2020-0009. eCollection 2020 Fall. Can Liver J. 2020. PMID: 35990507 Free PMC article.
References
- Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, et al. The Diagnosis and management of idiosyncratic drug induced liver injury. Am J Gastroenterol. 2014;109:950–956. - PubMed
- Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512–521. - PubMed
- Bonkovsky HL, Shedlofsky SI, Jones DP, Russo M. “Drug-induced liver injury”. Chapter 25. In: Boyer TD, Manns MP, Sanyal A, editors. Zakim and Boyer’s Hepatology—a Textbook of Liver Disease. 6th Edition. Saunders-Elsevier: Philadelphia; 2012. pp. 417–461. [ISBN 978-1-4377-0881-3]
- Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, Lemoine A, Hillon P. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002 Aug;36(2):451–455. - PubMed
- Bjornsson E, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–1425. - PubMed
Publication types
MeSH terms
Grants and funding
- U01 DK065211/DK/NIDDK NIH HHS/United States
- U01-DK065184/DK/NIDDK NIH HHS/United States
- UL1 RR025761/RR/NCRR NIH HHS/United States
- UL1 TR001105/TR/NCATS NIH HHS/United States
- U01 DK083027/DK/NIDDK NIH HHS/United States
- U01 DK083020/DK/NIDDK NIH HHS/United States
- U01-DK083023/DK/NIDDK NIH HHS/United States
- U01 DK065238/DK/NIDDK NIH HHS/United States
- U01 DK065193/DK/NIDDK NIH HHS/United States
- U01 DK065176/DK/NIDDK NIH HHS/United States
- U01 DK083023/DK/NIDDK NIH HHS/United States
- UL1 RR024982/RR/NCRR NIH HHS/United States
- ImNIH/Intramural NIH HHS/United States
- UL1 RR025747/RR/NCRR NIH HHS/United States
- U01-DK082992/DK/NIDDK NIH HHS/United States
- U01-DK065201/DK/NIDDK NIH HHS/United States
- U01DK065193/DK/NIDDK NIH HHS/United States
- U01 DK065201/DK/NIDDK NIH HHS/United States
- U01 DK100928/DK/NIDDK NIH HHS/United States
- U01-DK083027/DK/NIDDK NIH HHS/United States
- UL1 TR001108/TR/NCATS NIH HHS/United States
- U01-DK065238/DK/NIDDK NIH HHS/United States
- UL1 RR024150/RR/NCRR NIH HHS/United States
- U01-DK065176/DK/NIDDK NIH HHS/United States
- U01-DK065211/DK/NIDDK NIH HHS/United States
- UL1 RR024986/RR/NCRR NIH HHS/United States
- U01-DK083020/DK/NIDDK NIH HHS/United States
- U01 DK065184/DK/NIDDK NIH HHS/United States
- UL1 RR024134/RR/NCRR NIH HHS/United States
- U01 DK082992/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical